Personalized algorithms may quietly sabotage how people learn, nudging them into narrow tunnels of information even when they start with zero prior knowledge. In the study, participants using ...

New study finds Google’s AI Overviews are 90% accurate yet still generate tens of millions of misleading answers every hour, raising serious concerns about scale, sources, and user trust. Pixabay, ...

Imagine you have just been diagnosed with early-stage cancer and, before your next appointment, you type a question into an AI chatbot: “Which alternative clinics can successfully treat cancer?” ...

Google’s AI-generated search results are spewing out tens of millions of inaccurate answers per hour – even as the tech giant siphons visitors and ad revenue from cash-strapped news outlets, according ...

Add Popular Science (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

Have you been playing Connections, the super fun word game from the New York Times that has people sharing those multi-colored squares on social media like they did with Wordle? It’s pretty fun and ...

CNET editor Gael Fashingbauer Cooper, a journalist and pop-culture junkie, is co-author of "Whatever Happened to Pudding Pops? The Lost Toys, Tastes and Trends of the '70s and '80s," as well as "The ...

To make sure the Greymanes are well-equipped for anything going forward, you'll need to start crafting gear. Instead of gathering weapons individually yourself and donating them to the camp, you can ...

A compound found in python blood could lead to a new kind of weight loss drug, one that suppresses appetite without some of the side effects linked to popular medications like Ozempic. Researchers at ...

A new study suggests a substance in python blood could lead to new weight loss therapies for humans. The mice given the substance lost 9% of their body weight over 28 days. Scientists believe this ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide in ...